Oblon Ranked Top Patent Firm for Biotech, Pharma, & Life Sciences
For Immediate Release
August 17, 2017
Alexandria, VA – Oblon, McClelland, Maier & Neustadt, LLP, is proud to announce that the firm has been ranked as the number one patent firm for Biotech, Pharma, & Life Sciences by Juristat and second overall amongst all firms.
The ranking is based on four key metrics, as measured from January 1, 2011 to December 31, 2015. These metrics are: Number of Applications Filed, Allowance Rate, Average Number of Office Actions Before Allowance, and Average Time of Allowance with the ranking determined by a weighted average.
The firm attributes its high ranking to its Life Science Practice Group’s combination of a wide range of scientific, government and industry experience. The ranking confirms the Group’s knowledge of how the FDA rules and procedures can be leveraged in the patenting process. The Life Science Practice Group is co-headed by Stephen Baxter, Ph.D., and Richard Kelly.
Assisting clients for nearly 50 years, Oblon is one of the largest intellectual-property law firms in the United States. Oblon’s 110+ legal professionals provide a full range of intellectual-property services to some of the world’s leading innovators. The firm is headquartered within steps of the United States Patent and Trademark Office with an affiliate office in Tokyo, Japan.